Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes

被引：0

作者：

Reinisch, Mattea ^{[1
]}

Harbeck, Nadia ^{[2
]}

Rastogi, Priya ^{[3
,4
]}

O'shaughnessy, Joyce ^{[5
]}

Boyle, Frances ^{[6
]}

Cortes, Javier ^{[7
,8
]}

Rugo, Hope S. ^{[9
]}

Hamilton, Erika ^{[10
]}

Goetz, Matthew P. ^{[11
]}

Huang, Chiun-Sheng ^{[12
]}

Senkus, Elzbieta ^{[13
]}

Trakin, Alexey ^{[14
]}

Neven, Patrick ^{[15
]}

Huober, Jens ^{[16
]}

Ran, Wei ^{[17
]}

Andre, Valerie ^{[17
]}

Munoz-Fernandez, Maria ^{[17
]}

Antonio, Belen San ^{[17
]}

Shahir, Ashwin ^{[17
]}

Martin, Miguel ^{[18
]}

Johnston, Stephen ^{[19
]}

机构：

[1] Evang Kliniken Essen Mitte, Clin Gynecol, Breast Ctr, Essen, Germany

[2] LMU Univ Hosp, Comprehens Canc Ctr Munchen, Dept Gynecol & Obstet, Breast Ctr, Munich, Germany

[3] UPMC, Hillman Canc Ctr, Pittsburgh, PA USA

[4] NSABP Fdn, Pittsburgh, PA USA

[5] Baylor Univ, Texas Oncol, US Oncol, Med Ctr, Dallas, TX USA

[6] Univ Sydney, Sydney Med Sch 4, Sydney, NSW, Australia

[7] Quironsalud Grp, Int Breast Canc Ctr IBCC 5, Barcelona, Spain

[8] Int Breast Canc Ctr IBCC, Quironsalud Grp, Barcelona, Spain

[9] Univ Calif San Francisco, Dept Med, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[10] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA

[11] Mayo Clin, Rochester, MN USA

[12] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Surg, Coll Med, Taipei, Taiwan

[13] Med Univ Gdansk, Gdansk, Poland

[14] NN Blokhin Russian Canc Res Ctr, Moscow, Russia

[15] Univ Hosp Leuven, Multidisciplinary Breast Ctr, Louvain, Belgium

[16] Kantonsspital St Gallen, Breast Ctr, St Gallen, Switzerland

[17] Eli Lilly & Co, Indianapolis, IN USA

[18] Univ Complutense Madrid, Hosp Gen Univ Gregorio Maranon, CIBERONC, GEICAM, Madrid, Spain

[19] Royal Marsden NHS Fdn Trust, London, England

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2024年 / 47卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1085

引用

页码：227 / 228

页数：2

共 50 条

[21] Cost-effectiveness analysis of abemaciclib and endocrine therapy combination for the adjuvant treatment of HR+/HER2-, node-positive, high-risk, early breast cancer
Talwar, Ashna
Deshmukh, Ashish
Trivedi, Meghana
Aparasu, Rajender R.
CANCER RESEARCH, 2023, 83 (07)
[22] Abemaciclib combined with endocrine therapy as adjuvant treatment for hormone-receptor-positive, HER2-, high-risk early breast cancer: 5-year Chinese population analysis of the phase III randomized monarchE study
Zhang, Qingyuan
Shen, Kunwei
Song, Chuan-gui
Ouyang, Quchang
Liu, Zhenzhen
Liu, Qiang
Feng, Jifeng
Chiu, Joanne W. Y.
Tang, Jinhai
Jiang, Zefei
Tseng, Ling-Ming
Wang, Xiaojia
Yang, Liu
Qian, Chenxi
Shao, Zhimin
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
[23] Results from a pilot study exploring ctDNA detection using a tumor-informed assay in the monarchE trial of adjuvant abemaciclib with endocrine therapy in HR+, HER2-, node-positive, high-risk early breast cancer
Loi, Sherene
Johnston, Stephen
Arteaga, Carlos
Graff, Stephanie
Chandarlapaty, Sarat
Goetz, Matthew
Desmedt, Christine
Reis-Filho, Jorge
Sasano, Hironobu
Rodrik-Outmezguine, Vanessa
Sireci, Anthony
Rubenstein, Cynthia Sandoval
Won, Helen
Liu, Deli
Litchfield, Lacey M.
Turner, Nicholas
CANCER RESEARCH, 2024, 84 (09)
[24] Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2–early breast cancer in China
Qiran Wei
YuTing Xu
Wei Liu
Xin Guan
Cost Effectiveness and Resource Allocation, 21
[25] Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2-early breast cancer in China
Wei, Qiran
Xu, Yuting
Liu, Wei
Guan, Xin
COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
[26] Safety outcomes from monarchE: Phase 3 study of abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER-2-, node-positive, high risk, early breast cancer
Rugo, H.
O'Shaughnessy, J.
Song, C.
Broom, R.
Gumus, M.
Yamashita, T.
San Antonio, B.
Shahir, A.
Zimmermann, A.
Zagouri, F.
Reinisch, M.
BREAST, 2021, 56 : S23 - S24
[27] Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
Fleming, G. F.
Pagani, O.
Regan, M. M.
Walley, B. A.
Francis, P. A.
ANNALS OF ONCOLOGY, 2022, 33 (06) : 658 - 658
[28] Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
Harbeck, N.
Rastogi, P.
Martin, M.
Tolaney, S. M.
Shao, Z. M.
Fasching, P. A.
Huang, C. S.
Jaliffe, G. G.
Tryakin, A.
Goetz, M. P.
Rugo, H. S.
Senkus, E.
Testa, L.
Andersson, M.
Tamura, K.
Del Mastro, L.
Steger, G. G.
Kreipe, H.
Hegg, R.
Sohn, J.
Guarneri, V
Cortes, J.
Hamilton, E.
Andre, V
Wei, R.
Barriga, S.
Sherwood, S.
Forrester, T.
Munoz, M.
Shahir, A.
San Antonio, B.
Nabinger, S. C.
Toi, M.
Johnston, S. R. D.
O'Shaughnessy, J.
ANNALS OF ONCOLOGY, 2021, 32 (12) : 1571 - 1581
[29] Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study
Rugo, H. S.
O'Shaughnessy, J.
Boyle, F.
Toi, M.
Broom, R.
Blancas, I
Gumus, M.
Yamashita, T.
Im, Y-H
Rastogi, P.
Zagouri, F.
Song, C.
Campone, M.
San Antonio, B.
Shahir, A.
Hulstijn, M.
Brown, J.
Zimmermann, A.
Wei, R.
Johnston, S. R. D.
Reinisch, M.
Tolaney, S. M.
ANNALS OF ONCOLOGY, 2022, 33 (06) : 616 - 627
[30] Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2-, node-positive, high-risk early breast cancer in Italy
Davie, Alison
Traore, Sory
Giovannitti, Massimo
Pompilio, Giuseppe
Lambton, Mark
Cakar, Esra
Chatterjee, Anuja
GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2023, 10 : 62 - 69

← 1 2 3 4 5 →